(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Friday that the All-Wales Medicines Strategy Group (AWMSG) has recommended its 'Efmody' hydrocortisone modified-release hard capsules as an option for restricted use to treat adolescents and adults with congenital adrenal hyperplasia (CAH) within NHS Wales.
The AIM-traded firm said AWMSG's recommendation meant that Efmody was now available for use as a second-line treatment option in adolescents with CAH not adequately controlled on maximum guideline doses of immediate-release hydrocortisone, and as a third-line treatment in adults with CAH not adequately controlled on maximum guideline doses of immediate-release hydrocortisone or prednisolone.
It said it would roll-out Efmody commercially in Wales using its existing sales and marketing infrastructure and supply chain.
Efmody had been available for the treatment of CAH in the UK since launch in October 2021.
It was licensed for the treatment of congenital adrenal hyperplasia in adolescents aged 12 years and older, and in adults in Britain, by the Medicines and Healthcare products Regulatory Agency (MHRA).
"We are delighted that, after a rigorous review, the AWMSG has recognised the potential for Efmody to address important unmet needs in patients suffering with CAH," said interim chief executive officer Richard Bungay.
"Diurnal believes the use of this medicine will improve the lives of adults and adolescents in Wales living with this rare disease."
At 1100 BST, shares in Diurnal Group were down 0.92% at 26.9p.
Reporting by Josh White at Sharecast.com.
